Title: Frovatriptan
CAS Registry Number: 158747-02-5
CAS Name: (3R)-2,3,4,9-Tetrahydro-3-(methylamino)-1H-carbazole-6-carboxamide
Additional Names: 3-methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole
Manufacturers' Codes: SB-209509
Molecular Formula: C14H17N3O
Molecular Weight: 243.30
Percent Composition: C 69.11%, H 7.04%, N 17.27%, O 6.58%
Literature References: Serotonin 5-HT1B/1D receptor agonist. Prepn: F. D. King et al., WO 9300086; eidem, US 5464864 (1993, 1995 both to SmithKline Beecham). Pharmacology: A. A. Parsons et al., J. Cardiovasc. Pharmacol. 30, 136 (1997). Series of articles on pharmacology, safety and clinical studies: Headache 42, Suppl. 2, S45-S99 (2002). Review of clinical experience in cluster headaches: H. C. Siow et al., Cephalalgia 24, 1045-1048 (2004); in acute migraine: N. Poolsup et al., J. Clin. Pharm. Ther. 30, 521-532 (2005).
Derivative Type: Succinate monohydrate
CAS Registry Number: 158930-17-7; 158930-09-7 (anhydrous)
Manufacturers' Codes: SB-209509AX; VML-251
Trademarks: Frova (Vernalis); Frovelan (Elan); Migard (Vernalis); Miguard (Vernalis)
Molecular Formula: C14H17N3O.C4H6O4.H2O
Molecular Weight: 379.41
Percent Composition: C 56.98%, H 6.64%, N 11.08%, O 25.30%
Properties: White to off-white powder. Sol in water.
Therap-Cat: Antimigraine.
Keywords: Antimigraine; Serotonin Receptor Agonist.
Fructose Fructose-1,6-diphosphate Fructose-6-phosphate Fucosamine Fucosterol

Frovatriptan 2.png
Systematic (IUPAC) name
Clinical data
Trade names Frova
AHFS/ monograph
MedlinePlus a604013
Pregnancy cat. B3 (AU) C (US)
Legal status Prescription only
Routes Oral
Pharmacokinetic data
Bioavailability 20–30%
Metabolism Hepatic
Half-life 26 hours
Excretion Renal
CAS number 158930-17-7 N
ATC code N02CC07
PubChem CID 77992
DrugBank DB00998
ChemSpider 70378 YesY
KEGG D07997 N
Synonyms 6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
Chemical data
Formula C14H17N3O 
Mol. mass 243.304 g/mol
 N (what is this?)  (verify)

Frovatriptan (trade name Frova) is a triptan drug developed by Vernalis for the treatment of migraine headaches and for short term prevention of menstrual migraine. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.[1]